NCT07064668View on ClinicalTrials.gov

Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 30, 2027

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

TUDCA (Tauroursodeoxycholic Acid) Supplementation

TUDCA administered orally according to protocol-defined dosage.

DRUG

Immune checkpoint inhibitor (ICI)

Administered intravenously according to standard practice or protocol.

Trial Locations (1)

430000

Tongji Medical college of HUST, Wuhan

All Listed Sponsors
lead

Tongji Hospital

OTHER